We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBr.small Co.2 Regulatory News (BSC)

Share Price Information for Br.small Co.2 (BSC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 56.50
Bid: 55.50
Ask: 57.50
Change: 0.00 (0.00%)
Spread: 2.00 (3.604%)
Open: 56.50
High: 56.50
Low: 56.50
Prev. Close: 56.50
BSC Live PriceLast checked at -
British Smaller Companies VCT 2 is an Investment Trust

To create a portfolio that blends a mix of businesses operating in established industries with those that offer opportunities in the application and development of innovation.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Management Statement

23 Nov 2015 12:24

RNS Number : 6295G
British Smaller Companies VCT2 Plc
23 November 2015
 



 

British Smaller Companies VCT2 plc

Interim Management Statement

For the quarter ended 30 September 2015

British Smaller Companies VCT2 plc (the "Company") presents its interim management statement for the quarter ended 30 September 2015. The statement also includes relevant financial information between the end of the quarter and the date of this statement. A copy of this interim management statement can be found at www.bscfunds.com.

Overview

The Company has continued to make good progress in the quarter with total return rising to 109.1 pence per ordinary share. This is an increase of 2.7 pence per ordinary share in the first nine months of the year; equivalent to 4.3% of the opening Net Asset Value ('NAV').

Since the March 2015 Budget, when prospective changes to the rules impacting venture capital trusts were announced, there has been some uncertainty about the timing and precise detail of the changes. As each new investment that is made has required HMRC advanced assurance this has resulted in a considerable slowdown of new investment activity until clarity over the proposed changes became clear. Consequently no new investments were completed between 25 March 2015 and the quarter end.

However, in advance of the new Finance Bill, which received Royal Assent on 18 November 2015, advanced assurances have again begun to be received. As a consequence since the quarter end the Company has completed 1 new investment of £2.0 million into KeTech Enterprises Limited and two follow-on investments totalling £0.6 million. A further two new investments totalling £1.7 million and one follow-on investment of £0.2 million have also been approved by the Board bringing investment activity levels since the end of the period to £4.5 million. This level of activity is more in line with the levels that have been experienced prior to the March 2015 budget.

 

Performance

30 September 2015

Movement

30 June 2015

Net Assets (£m)

53.3

(0.8)

54.1

NAV per share (PPS)

61.1

(1.4)

62.5

Cumulative dividends paid (PPS)

48.0

2.0

46.0

Total Return (PPS)

109.1

0.6

108.5

Shares in issue

87,262,575

581,009

86,681,566

 

The total return at 30 September 2015, calculated by reference to the NAV per ordinary share and the cumulative dividends paid per ordinary share, was 109.1 pence per ordinary share compared to 108.5 pence per ordinary share at 30 June 2015. Following payment of a 2.0 pence per ordinary share interim dividend cumulative dividends paid have increased to 48.0 pence per ordinary share (30 June 2015: 46.0 pence per ordinary share).

The unaudited NAV per ordinary share as at 30 September 2015 was 61.1 pence per ordinary share (30 June 2015: 62.5 pence per ordinary share) representing a decrease of 1.4 pence per ordinary share. The decrease in NAV per ordinary share is due to the interim dividend of 2.0 pence per ordinary share paid on 28 September 2015, offset by the net upward movement in the overall portfolio valuation.

 

Dividends and shares in issue

The number of ordinary shares in issue at 30 September 2015 was 87,262,575 (30 June 2015: 86,681,566). In addition, at 30 September 2015 the Company held 2,128,003 ordinary shares in treasury (30 June 2015: 2,128,003).

On 28 September 2015 the Company paid an interim dividend of 2.0 pence per ordinary share. Pursuant to its dividend re-investment scheme and on the same date the Company issued 581,009 ordinary shares at a price of 57.48 pence per ordinary share.

 

Net assets

Net assets at 30 September 2015 comprised the following:

£000

% of net assets

Unquoted investments at fair value

31,229

58.6

Quoted investments at bid price

2,641

5.0

Total investments

33,870

63.6

Cash and cash equivalents

18,703

35.1

Other net current assets

711

1.3

Net assets

53,284

100.0

 

   

The investment portfolio at 30 September 2015 was comprised as follows:

Valuation

£000

Valuation as a % of net assets

Intelligent Office

3,059

5.7

Mangar Health Limited

2,026

3.8

DisplayPlan Holdings Limited

1,860

3.5

Gill Marine Holdings Limited

1,764

3.3

GTK (Holdco) Limited

1,470

2.8

ACC Aviation

1,379

2.6

Business Collaborator Limited

1,340

2.5

Immunobiology Limited

1,311

2.5

Harvey Jones Holdings Limited

1,301

2.4

Springboard Research Holdings Limited

1,241

2.3

16,751

31.4

Other investments

17,119

32.2

Total investments

33,870

63.6

 

During the quarter to 30 September 2015 the Company made two investments totalling £0.4 million: one follow-on investment of £0.3 million into Immunobiology Limited and £0.1 million of additional investment into AIM listed Brady plc.

In the quarter to 30 September 2015 the realisation and repayment of investments generated cash proceeds of £0.2 million. Since the end of the quarter the Company has realised its investment in Insider Technologies for proceeds of £0.8 million, an increase of £0.3 million over the value at the beginning of the financial year and received loan repayments of £0.4 million.

Portfolio Performance

Over the quarter to 30 September 2015 aggregate unrealised portfolio valuations have increased by £0.4 million. This included a £0.2 million uplift in respect of the investment in Insider Technologies, which as above was realised following the quarter end.

The Board continues to follow its policy of maintaining a diversified portfolio. At 30 September 2015, only one investment represented more than 5 per cent of the Company's NAV.

Regulatory Changes

By way of background. The changes that have been introduced this year to the regulations surrounding VCTs (and EIS) have arisen as a result of an EU review of the use of state-aided investment. The EU has a set of guidelines, Risk Capital Finance (RCF) which sets out the operating framework for investment schemes that receive state aid. In the case of VCTs the income tax reliefs received are state aid. These guidelines were the subject of some revision with the latest set coming into force on 1 January 2015.

The UK legislation that has now been enacted as part of the Finance Bill includes changes to reflect the requirements of the RCF and VCTs have to comply with both the UK legislation and the RCF and are subject to review by both HMRC and HM Treasury and the EU.

The principal changes that have been made are to the definitions of Qualifying Investments and what VCTs are able to do with non-qualifying money.

In summary Qualifying Investments can be made into both younger companies, those less than ten years old if classed as knowledge intensive, or seven years old if not and older companies where the VCT investment is either not the first state aided investment the company has received or that the VCT investment is "substantial in relation to the size of the company" and the monies are used to fund the company's growth plans.

There are also restrictions on the use of funds prior to them being invested in Qualifying Investments; this is known in the legislation as the liquidity test. This is restricted to shares or securities on a regulated market; certain liquid funds and of course cash. Notably AIM is excluded as it is not a regulated market, which means new non-qualifying investments on AIM will not be allowed.

 

Impact of the Regulatory Changes

 

 Existing portfolio

The new rules apply to all investments from 18 November 2015, the date of Royal Assent. The Board has worked closely with its Adviser to review the existing portfolio against the new legislation and does not believe that there will be any material impact on the portfolio.

 New investments

The Company has always had a policy of investing in small companies to support their growth plans and will be able to continue to follow this policy under the new legislation. The Board believes that the overall pool of potential investments available to the VCT market as a whole will be restricted from previous levels, which is the purpose of the legislative changes.

The Board has taken a cautious approach to the new legislation with a policy of only completing investments on which HMRC advanced assurance is given, which itself is only granted for investments that meet the Qualifying Investment test. It is encouraging that as the legislation has been finalised advanced assurances are now being given and we are seeing the flow of investment activity resume. HMRC's detailed guidance is planned to be issued shortly and it is expected that this will further increase the number of advanced assurances that can be given.

Fundraising

With the Company now receiving advanced assurances from HMRC in respect of new investments and on reviewing the pipeline of current opportunities the Board has determined that in the current tax year it will launch a non-prospectus share offer. Details will be made available to existing shareholders in the near future. The offer is limited, by EU Regulation, to €5.0 million which is anticipated to equate approximately to £3.5 million.

 

Outlook

The Board continues to see opportunities to add value to growing businesses across a variety of sectors, with a number of investments at an advanced stage. The portfolio continues to generate good returns and a number of investments are well positioned to realise value for shareholders in the medium term.

 

23 November 2015

 

For further information please contact:

David Hall YFM Private Equity Limited Tel: 0113 244 1000

Gillian Martin Nplus1 Singer Advisory LLP Tel: 0207 496 3000

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSZMMZMZFZGKZM
Date   Source Headline
3rd Apr 20248:04 amRNSDirector/PDMR Shareholding
3rd Apr 20248:04 amRNSDirector/PDMR Shareholding
3rd Apr 20247:57 amRNSIssue of Equity and Close of Offers
26th Mar 202411:10 amRNSTransaction in Own Shares and Total Voting Rights
21st Mar 20247:40 amRNSAppointment of non-executive Director
20th Mar 202412:00 pmRNSPublication of Supplementary Prospectus
20th Mar 202412:00 pmRNSPublication of Supplementary Prospectus
15th Mar 202412:15 pmRNSAnnual Financial Report
16th Feb 20243:52 pmRNSClose of Offers to New Applications
16th Feb 20243:51 pmRNSClose of Offers to New Applications
30th Jan 20249:26 amRNSDirector/PDMR Shareholding
30th Jan 20249:24 amRNSDirector/PDMR Shareholding
30th Jan 20249:24 amRNSIssue of Equity
18th Dec 20234:04 pmRNSTransaction in Own Shares
13th Dec 20234:00 pmRNSOffer Update
13th Dec 20234:00 pmRNSStrategy/Company/Ops Update
24th Nov 20237:00 amRNS3rd Quarter Results
3rd Nov 20239:40 amRNSPayment of dividend and issue of equity
24th Oct 20231:20 pmRNSOffer Update
24th Oct 20231:19 pmRNSOffer Update
6th Oct 202310:19 amRNSOffer Update
6th Oct 202310:17 amRNSOffer Update
27th Sep 20238:21 amRNSOffer Update
26th Sep 20238:16 amRNSTransaction in Own Shares
20th Sep 202312:30 pmRNSPublication of a Prospectus
20th Sep 202312:30 pmRNSPublication of a Prospectus
13th Sep 20237:00 amRNSHalf-year Report
2nd Aug 202310:25 amRNSNew combined offer for subscription
2nd Aug 202310:25 amRNSNew combined offer for subscription
27th Jun 20237:46 amRNSTransaction in Own Shares
26th Jun 202310:57 amRNSDirector/PDMR Shareholding
26th Jun 202310:56 amRNSPayment of Dividend and Issue of Equity
16th Jun 202312:00 pmRNS1st Quarter Results
15th Jun 20233:17 pmRNSResult of Meeting
15th Jun 20233:16 pmRNSResult of AGM
4th Apr 20233:25 pmRNSDirector/PDMR Shareholding
4th Apr 20233:25 pmRNSDirector/PDMR Shareholding
4th Apr 20233:24 pmRNSDirector/PDMR Shareholding
4th Apr 20233:22 pmRNSIssue of Equity and Close of Offers
29th Mar 20238:40 amRNSTransaction in Own Shares
27th Mar 20236:00 pmRNSClose of Offers to new Applications
27th Mar 20236:00 pmRNSClose of Offers to new Applications
23rd Mar 202311:30 amRNSPublication of Circular
22nd Mar 202312:15 pmRNSPublication of Supplementary Prospectus
22nd Mar 202312:15 pmRNSPublication of Supplementary Prospectus
20th Mar 20233:00 pmRNSAnnual Financial Report
14th Feb 20234:35 pmRNSOffer Update
14th Feb 20234:35 pmRNSOffer Update
11th Jan 202310:00 amRNSPayment of Dividend and Issue of Equity
19th Dec 20228:50 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.